Stock Analiz

Beta Bionics, Inc. BBNX

Medical/Dental Instruments · IPO 2025 · data as of November 13, 2026

$16.42Market cap $893M
Open the interactive analysis →

Beta Bionics, Inc. (BBNX) is a healthcare company listed in the US with a market value of about $893M. In the twelve months to September 30, 2026 it had revenue of $127M and net income of -$83M, a net margin of -65.3%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -19%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 89% below the current price.

About Beta Bionics

Beta Bionics is listed in the US and classified in medical/dental instruments, IPO year 2025. It was profitable in 0 of the last 3 years in our data. It spends 35% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S7.0
P/B2.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-7.4%
Shareholder yield0.0%
Intrinsic value vs. price−89%

Growth and quality

Revenue growth (1 yr)53.9%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-174.9%
ROIC (5-yr avg.)-19.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 3 years

Fiscal yearTTM202520242023
Revenue$127M$100M$65M$12M
Net income-$83M-$73M-$55M-$44M
Free cash flow-$66M-$56M-$52M-$33M
EPS (diluted)$-1.83$-1.81$-8.60$-8.31
Net margin-65.3%-73.0%-84.1%-367.6%
ROIC—-19.2%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 14 analysts is $25.10, 53% above the current price; targets range from $16.00 to $30.40; the consensus rating is “Buy”; expected EPS is $-1.83 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Beta Bionics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 89% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Beta Bionics pay a dividend?

Not currently.

Is Beta Bionics a good stock to buy?

We do not give buy or sell advice. Beta Bionics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.